trial · primary record
Antigen-specific CAR T, CTL and DCvac to treat melanoma.
Melanoma
| Phase | Phase 1, Phase 2 |
|---|---|
| Status | RECRUITING |
| Sponsor | Unknown |
| Enrolment | 30 |
| Primary completion | 2029-12-31 |
| Primary endpoint | Number of patients with adverse events |
| Registry ID | NCT06739226 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-10-30T14:45:16.563Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT06739226
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.